Journal for ImmunoTherapy of Cancer

POSTER PRESENTATION



Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer

Lance D Miller^{1*}, Jeff W Chou², Michael A Black³, Cristin G Print⁴, Eric Jimenez¹, Julia Chifman¹, Angela Alistar¹, Thomas C Putti⁵, Xiaobo Zhou⁶, Davide Bedognetti⁷, Ashok Pullikuth⁸, Eran Andrechek⁹, Ena Wang¹⁰, Francesco M Marincola⁷

From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014

The abundance and functional orientation of tumorinfiltrating effector cells has long been observed to predict for reduced incidence of clinical metastasis and cancer-specific death. Using bioinformatics to mine large breast tumor microarray datasets, we and others have identified prognostic immune gene signatures, or metagenes. Robust evidence indicates that these metagenes are: 1) positively correlated with distant metastasis-free survival (DMFS) of patients, 2) comprised of genes that regulate immune cell-specific biology, and 3) reflective of the relative abundance of discernible populations of tumor infiltrating leukocytes. In recent work we have leveraged the statistical associations between the immune metagenes and the DMFS of breast cancer patients to explore the underlying phenotypes that differ in their ability to potentiate long-term, immunemediated tumor rejection. Using a tumor classification model that combines the prognostic attributes of three distinct immune metagenes, termed the B/P, T/NK and M/D metagenes, we have identified molecular subtypes of breast cancer that either permit or prohibit prognostication by the immune metagenes. On this basis, we have delineated the phenotypic attributes of breast cancer that distinguish two novel immunogenic tumor subtypes, which we have defined as: immune benefit-enabled (IBE) and *immune benefit-disabled* (IBD). Phenotypically, IBE tumors comprise of Basal-like tumors and highly-proliferative HER2-Enriched and Luminal-B subtypes, while IBD tumors


comprise of Claudin-Low, Luminal-A, and low-proliferative HER2-Enriched and Luminal-B tumors. Prognostically, IBE tumors (n = 666) can be stratified by the immune metagene model into prognostic subgroups with high statistical significance (P<0.0001,log-rank test), while IBD tumors cannot (n = 1005, P = 0.3) consistent with the capacity for an innate anti-tumor immunity against IBE tumors, but not IBD tumors, that guards against distant metastasis. Furthermore, these observations were independent of adjuvant treatment, and may owe to differential activation of immunomodulatory pathways. Network analysis revealed that IBE/IBD differentially-expressed genes (q<0.01) underlie highly-significant pathway activation scores for TGF-beta signaling in IBD (p < 0.0001), and Interferon-gamma signaling in IBE (p < 0.0001). Furthermore, 15 of 19 genes comprising the previously described Immunologic Constant of Rejection (Marincola and colleagues) were significantly overexpressed in IBE tumors (P-value range: 0.05-3.5E-14). Thus, we conclude that breast tumors can be dichotomized into two subtypes fundamentally distinct with respect to their potential for metastasis-protective immune responsiveness. These findings indicate new contexts for studying anti-tumor immunity and oncogenic mechanisms of immunosuppression in breast cancer. Whether IBE and IBD subtypes represent clinically-relevant contexts for assessing patient prognosis or evaluating the efficacy of immunotherapeutic treatments warrants further investigation (See Figure 1).

¹Wake Forest School of Medicine, Winston Salem, NC, USA

Full list of author information is available at the end of the article



© 2014 Miller et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



(rows) across 1,954 tumors (columns). Key shows color scale of mean centered, log2-transformed gene signal intensities. For each metagene, tumors are aligned by ascending metagene scores; tertile thresholds are show (33rd and 66th percentiles) for defining low (L), intermediate (I) and high (H) metagene tertiles. **(B)** IMM prognostic risk groups are shown. **(C, D)** IBE and IBD type tumors are shown stratified by IMM subclasses (FID, WID, PID) in Kaplan-Meier plots of DMFS. The number of tumors (n) in each subclass is shown; the log-rank p-value is reported.

Authors' details

¹Wake Forest School of Medicine, Winston Salem, NC, USA. ²Wake Forest Public Health Sciences, Department of Biostatistical Sciences, Winston Salem, NC, USA. ³University of Otago, New Zealand. ⁴School of Medical Sciences and Bioinformatics Institute, University of Auckland, New Zealand. ⁵National University of Singapore, Yong Loo Lin School of Medicine, Department of Pathology, Singapore, ⁶Wake Forest School of Medicine, Division of Radiologic Sciences, Center for Bioinformatics and Systems Biology, Winston Salem, NC, USA. ⁷Sidra Medical and Research Center, Qatar. ⁸Wake Forest School of Medicine, Department of Cancer Biology, Winston Salem, NC, USA. ⁹Michigan State University, Department of Physiology, East Lansing, MI, USA. ¹⁰Sidra Medical and Research Center, Division of Translational Medicine, Qatar.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P256

Cite this article as: Miller *et al.*: Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P256.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central